The incidence of type 1 diabetes is increasing worldwide. Current therapy continues to be suboptimal.
An exciting therapeutic advance in the short term is closed loop technology development and application. However, cell and tissue therapy continues to be an unmet need for the disorder.
Human islets isolated from deceased donors will be clinically available to treat type 1 diabetes within the next 1 to 2 years. Other approaches such as xenotransplantation and islet products derived from human embryonic stem cells and induced pluripotent stem cells are currently being pursued.
The current commentary provides context and discusses future endeavors for transplantation of islet-like structures derived from fetal pancreas.
Author: Yasuhiro IkedaYogish C Kudva
Credits/Source: Stem Cell Research Therapy 2013, 4:159
Published on: 2013-12-30
Tweet
News Provider: EUPB – European Press Bureau
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
There are no comments available. Be the first to write a comment.